Solid-tumor cancer patients ineligible for clinical trials receive more immunotherapy but may not benefit
Health practitioners rely on case management programs to address patients’ social care needs
9 November 2021Researchers reveal critical role of mechanosensor in skin wound healing
9 November 2021Solid-tumor cancer patients ineligible for clinical trials receive more immunotherapy but may not benefit
Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania. The study, published in JAMA Oncology, suggests that the positive results for phase 3 clinical trial participants receiving ICI treatment may not translate to patients who are ineligible for trials due to factors such as organ dysfunction.
